Get the Stockscreener App
37.92
3.63%
-1.43
Mineralys Therapeutics Inc stock is traded at $37.92, with a volume of 1.47M.
It is down -3.63% in the last 24 hours and up +144.96% over the past month.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
See More
Previous Close:
$39.35
Open:
$39.22
24h Volume:
1.47M
Relative Volume:
0.99
Market Cap:
$2.51B
Revenue:
-
Net Income/Loss:
$-119.67M
P/E Ratio:
-13.89
EPS:
-2.73
Net Cash Flow:
$-97.30M
1W Performance:
+0.72%
1M Performance:
+144.96%
6M Performance:
+138.79%
1Y Performance:
+213.13%
1-Day Range:
$37.84
$40.18
1-Week Range:
$37.51
$41.09
52-Week Range:
$8.241
$41.09
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
Name
Mineralys Therapeutics Inc
Sector
Industry
Phone
(888) 378-6240
Address
150 N. RADNOR CHESTER ROAD, RADNOR
Compare MLYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
37.92 | 3.05B | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Initiated | Jefferies | Hold |
| Jul-10-24 | Initiated | H.C. Wainwright | Buy |
| Apr-02-24 | Initiated | Goldman | Buy |
| Mar-07-23 | Initiated | BofA Securities | Buy |
| Mar-07-23 | Initiated | Credit Suisse | Outperform |
| Mar-07-23 | Initiated | Evercore ISI | Outperform |
| Mar-07-23 | Initiated | Guggenheim | Buy |
| Mar-07-23 | Initiated | Stifel | Buy |
| Mar-07-23 | Initiated | Wells Fargo | Overweight |
View All
Mineralys Therapeutics Inc Stock (MLYS) Latest News
Mineralys completes enrollment in phase 2 sleep apnea drug trial By Investing.com - Investing.com Australia
What does recent volatility data suggest for Mineralys Therapeutics Inc.Risk Management & Weekly High Conviction Ideas - newser.com
Mineralys at Stifel Forum: Lorundrostat’s Strategic Path - Investing.com India
Mineralys at Stifel Forum: Lorundrostat’s Strategic Path By Investing.com - Investing.com Canada
Mineralys Therapeutics, Inc. (MLYS) Shows Positive Phase 3 HTN Results, Blood Pressure Drops in High-Risk Groups - Yahoo Finance
Mineralys Therapeutics Completes Phase 2 Trial Enrollment for Lorundrostat in Obstructive Sleep Apnea, Hypertension - MarketScreener
Mineralys Therapeutics completes enrollment in Phase 2 EXPLORE-OSA trial - TipRanks
Mineralys completes enrollment in phase 2 sleep apnea drug trial - Investing.com India
Mineralys Therapeutics Completes Enrollment in Phase 2 - GlobeNewswire
Sleep Apnea Breakthrough: Mineralys's Novel Drug Trial Targets Nighttime Blood Pressure Control - Stock Titan
Voya Investment Management LLC Acquires Shares of 16,058 Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Will Mineralys Therapeutics Inc. see short term momentumEarnings Miss & Community Verified Trade Signals - newser.com
What’s next for Mineralys Therapeutics Inc. stock priceCEO Change & Weekly Momentum Picks - newser.com
Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock: Should You Buy? - Yahoo Finance
Mineralys Therapeutics (NASDAQ:MLYS) Sets New 52-Week HighShould You Buy? - MarketBeat
Tools to assess Mineralys Therapeutics Inc.’s risk profileWeekly Trend Summary & Fast Moving Trade Plans - newser.com
Tick level data insight on Mineralys Therapeutics Inc. volatility2025 Investor Takeaways & Real-Time Sentiment Analysis - newser.com
Mineralys Therapeutics prices $175M stock offering - MSN
Mineralys Therapeutics Inc.’s volatility index tracking explainedJuly 2025 Pullbacks & Weekly High Conviction Trade Ideas - newser.com
Statistical indicators supporting Mineralys Therapeutics Inc.’s strengthPortfolio Return Summary & Low Drawdown Momentum Ideas - newser.com
Understanding Mineralys Therapeutics Inc.’s price movementBull Run & Growth-Oriented Investment Plans - newser.com
Mineralys surges 53% on pivotal data for hypertension asset lorundrostat - MSN
Mineralys Therapeutics Delivers Financial Update and Advances Pipeline for Lorundrostat - MSN
Strs Ohio Takes Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics (MLYS): Evaluating Valuation Following Positive Phase 3 Blood Pressure Trial Results - simplywall.st
1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP) - AOL.com
Published on: 2025-09-23 04:04:25 - newser.com
Rhumbline Advisers Sells 1,195 Shares of Mineralys Therapeutics, Inc. $MLYS - Defense World
Forecasting Mineralys Therapeutics Inc. price range with options dataMarket Weekly Review & Low Volatility Stock Suggestions - newser.com
Why Replimune Stock Plummeted by Almost 40% Today - AOL.com
Published on: 2025-09-22 12:36:18 - newser.com
Is Mineralys Therapeutics Inc. stock poised for growth2025 Retail Activity & Real-Time Volume Triggers - newser.com
Mineralys Therapeutics, Inc. $MLYS Stock Position Lifted by Swedbank AB - MarketBeat
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives $43.50 Average Price Target from Analysts - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Hits New 52-Week HighShould You Buy? - MarketBeat
These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? - MSN
Miracle or Bubble? These 2 Healthcare Stocks Doubled in Less Than a Month - NAI500
Why Mineralys Therapeutics (MLYS) Is Up 5.8% After Strong Phase 3 Hypertension Data and FDA Update - simplywall.st
MLYS Stock Price and Chart — NASDAQ:MLYS - TradingView
Goldman Sachs Group Inc. Boosts Stake in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys Therapeutics Inc. stock outlook for YEARJuly 2025 Sentiment & Detailed Earnings Play Strategies - newser.com
Aug Analyst Calls: Is Senstar Technologies Corporation attractive for institutional investorsTrade Analysis Summary & Advanced Swing Trade Entry Alerts - khodrobank.com
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells 11,367 Shares of Stock - MarketBeat
Aug Chart Watch: Is Mineralys Therapeutics Inc impacted by rising ratesJuly 2025 Intraday Action & Weekly High Return Stock Forecasts - خودرو بانک
Mineralys Therapeutics Hits New 52-Week High at $40.33, Up 195% - Markets Mojo
Market reaction to Mineralys Therapeutics Inc.’s recent news2025 Big Picture & Capital Efficiency Focused Ideas - newser.com
3 Potential Biotech Acquisition Targets - Seeking Alpha
Performance Recap: Will Mineralys Therapeutics Inc. announce a stock splitMarket Growth Summary & Safe Entry Momentum Tips - khodrobank.com
Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 5%What's Next? - MarketBeat
Movement Recap: What’s Mineralys Therapeutics Inc.’s historical return - خودرو بانک
Mineralys Therapeutics stock hits all-time high at 39.23 USD By Investing.com - Investing.com Canada
Mineralys Therapeutics Inc Stock (MLYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):